Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials. [electronic resource]
Producer: 20161213Description: 334-41 p. digitalISSN:- 1433-2981
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Axitinib
- Benzimidazoles -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Indazoles -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Prognosis
- Quinolines -- administration & dosage
- Quinolones -- administration & dosage
- Randomized Controlled Trials as Topic
- Sorafenib
- Survival Rate
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.